EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

β-cyclodextrin-based nanosponges-in-nanowafers: A potential nanotherapeutic carrier in polycystic ovary syndrome

Sakshi Kothawade, Francesco Trotta, Pravin Shende

Materials Today Communications · 2026-12 · 57 · 116461

DOI: 10.1016/j.mtcomm.2026.116461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Materials Today Communications, 2026-12. Verfasst von Sakshi Kothawade und 2 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The challenges associated with treating PCOS and related symptoms, such as hyperandrogenism, ovulatory failure, and polycystic ovaries, show limitations using conventional vaginal formulations like gels and pessaries. Spironolactone, an antiandrogenic mineralocorticoid receptor antagonist, inhibits androgen receptors to target hyperandrogenism. To combat hyperandrogenism in PCOS, this research focused on the formulation, characterization, and optimization of spironolactone nanosponges-in-nanowafers. The polymer condensation method was employed to prepare the nanosponges, and then added to the nanowafers. These nanowafers offered regulated release, extended retention, and decreased toxicity of the drug with significant drug loading. The optimized formulation of nanosponges (DNSI) displayed a particle size of 403.56 ± 0.18 nm with an excellent entrapment efficiency of 89.84 ± 0.005%, sustained drug release, improved drug stability, reduced toxicity, and enhanced targeting to the vaginal site. The formulation DNSI exhibited a favorable in vitro release profile of 85.95 ± 8.31% for 72 h in simulated vaginal fluid. Additionally, nanowafers (CA: SA of 1:4 ratio) loaded with SP-loaded nanosponges demonstrated a particle size of 440.97 ± 0.16 nm, with 69.35 ± 2.76% drug release over a longer period in simulated vaginal fluid. Thus, nanowafers showed promising potential for an antiandrogenic effect in PCOS and could serve as a viable treatment alternative.

Zitieren

APA

Kothawade, S., Trotta, F., & Shende, P. (2026). β-cyclodextrin-based nanosponges-in-nanowafers: A potential nanotherapeutic carrier in polycystic ovary syndrome. Materials Today Communications, 57, 116461. https://doi.org/10.1016/j.mtcomm.2026.116461

Vancouver

Kothawade S, Trotta F, Shende P. β-cyclodextrin-based nanosponges-in-nanowafers: A potential nanotherapeutic carrier in polycystic ovary syndrome. Materials Today Communications. 2026;57:116461. doi:10.1016/j.mtcomm.2026.116461

BibTeX
@article{Kothawade2026,
  author = {Kothawade, Sakshi and Trotta, Francesco and Shende, Pravin},
  title = {β-cyclodextrin-based nanosponges-in-nanowafers: A potential nanotherapeutic carrier in polycystic ovary syndrome},
  journal = {Materials Today Communications},
  year = {2026},
  volume = {57},
  pages = {116461},
  doi = {10.1016/j.mtcomm.2026.116461}
}
Kostenlos starten →